An overview on mechanism, cause, prevention and multi-nation policy level interventions of dietary iron deficiency.


Journal

Critical reviews in food science and nutrition
ISSN: 1549-7852
Titre abrégé: Crit Rev Food Sci Nutr
Pays: United States
ID NLM: 8914818

Informations de publication

Date de publication:
2022
Historique:
pubmed: 6 2 2021
medline: 1 7 2022
entrez: 5 2 2021
Statut: ppublish

Résumé

Iron deficiency anemia (IDA) is probably the most ignored situation in the world of malnutrition-largely due to its slow progression. Multiple reasons can be attributed as the cause of IDA, which is not limited to any specific region or population; therefore, making it a matter of global concern. Despite the human body's ability to absorb and conserve iron stores, the gradual loss due to various physiological conditions leads to net deficiency of iron. Countless commercial iron supplements are available, but at given physiological conditions, almost all of these "Bio-not-available" iron forms quite often become ineffective. World Health Organization and other government bodies have jointly developed health advisories and tried to developed nutrition supplements several times in the last two decades. IDA, when combined with other disease conditions, becomes a life-threatening situation. At the same time, an overdose of iron could also be very harmful to the body. Therefore, it is important to deal with this situation with caution. This article covers iron metabolism, available options for iron supplementation, regulatory aspects and strategies to prevent IDA.

Identifiants

pubmed: 33543636
doi: 10.1080/10408398.2021.1879005
doi:

Substances chimiques

Iron, Dietary 0
Iron E1UOL152H7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4893-4907

Auteurs

Abhishek Kulkarni (A)

Synthetic Biology Group, Reliance Corporate Park, Reliance Industries Limited, Ghansoli, Navi Mumbai, India.

Monika Khade (M)

Synthetic Biology Group, Reliance Corporate Park, Reliance Industries Limited, Ghansoli, Navi Mumbai, India.

Sharadha Arun (S)

Synthetic Biology Group, Reliance Corporate Park, Reliance Industries Limited, Ghansoli, Navi Mumbai, India.

Pranesh Badami (P)

Synthetic Biology Group, Reliance Corporate Park, Reliance Industries Limited, Ghansoli, Navi Mumbai, India.

G Raja Krishna Kumar (GRK)

Synthetic Biology Group, Reliance Corporate Park, Reliance Industries Limited, Ghansoli, Navi Mumbai, India.

Tomal Dattaroy (T)

Synthetic Biology Group, Reliance Corporate Park, Reliance Industries Limited, Ghansoli, Navi Mumbai, India.

Badrish Soni (B)

Synthetic Biology Group, Reliance Corporate Park, Reliance Industries Limited, Ghansoli, Navi Mumbai, India.

Santanu Dasgupta (S)

Synthetic Biology Group, Reliance Corporate Park, Reliance Industries Limited, Ghansoli, Navi Mumbai, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH